N K Cheung Selected Research

CVACE protocol

1/2001

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

N K Cheung Research Topics

Disease

24	Neuroblastoma 01/2017 - 03/2000
23	Neoplasms (Cancer) 01/2017 - 03/2000
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2017 - 03/2000
3	Residual Neoplasm 07/2015 - 11/2000
2	Leukemia 01/2017 - 03/2000
2	Disease Progression 07/2001 - 01/2001
2	Pain (Aches) 01/2001 - 11/2000
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2017
1	Melanoma (Melanoma, Malignant) 04/2015
1	Wounds and Injuries (Trauma) 06/2007
1	Brain Neoplasms (Brain Tumor) 09/2001
1	Ewing Sarcoma (Sarcoma, Ewing) 08/2001
1	Triploidy 07/2001
1	Mucositis 01/2001
1	Urticaria (Hives) 01/2001
1	Mycoses (Diseases, Fungus) 11/2000
1	Neutropenia 11/2000
1	Thrombocytopenia (Thrombopenia) 11/2000
1	Infections 11/2000
1	Hepatocellular Carcinoma (Hepatoma) 09/2000

Drug/Important Bio-Agent (IBA)

10	Monoclonal AntibodiesIBA 11/2001 - 03/2000
4	Biological ProductsIBA 09/2001 - 09/2000
4	Immunoglobulin G (IgG)IBA 05/2001 - 07/2000
3	Bispecific AntibodiesIBA 01/2017 - 04/2015
3	AntibodiesIBA 04/2015 - 07/2000
3	DNA (Deoxyribonucleic Acid)IBA 07/2001 - 03/2000
3	Complement System Proteins (Complement)IBA 07/2000 - 03/2000
2	Pharmaceutical PreparationsIBA 01/2017 - 09/2001
2	Topotecan (Hycamtin)FDA LinkGeneric 09/2001 - 11/2000
2	Alkylating AgentsIBA 09/2001 - 11/2000
2	(N- acetylneuraminyl)- galactosylglucosylceramide N-acetylgalactosaminyltransferaseIBA 08/2001 - 06/2001
2	AntigensIBA 05/2001 - 03/2000
2	Surface Antigens (Surface Antigen)IBA 05/2001 - 03/2000
2	Vincristine (Oncovin)FDA LinkGeneric 01/2001 - 11/2000
2	LigandsIBA 12/2000 - 09/2000
2	Ephrin-B3 (Ephrin B3)IBA 12/2000 - 09/2000
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2000 - 11/2000
2	CD55 Antigens (Decay Accelerating Factor)IBA 06/2000 - 03/2000
1	RetinoidsIBA 01/2017
1	Isotretinoin (Accutane)FDA LinkGeneric 07/2015
1	Single-Chain AntibodiesIBA 04/2015
1	trans-sodium crocetinate (crocetin)IBA 04/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2015
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2001
1	CytokinesIBA 10/2001
1	Carboplatin (JM8)FDA LinkGeneric 09/2001
1	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 09/2001
1	GD2 gangliosideIBA 08/2001
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2001
1	Fluorine-18IBA 07/2001
1	Messenger RNA (mRNA)IBA 06/2001
1	8H9 monoclonal antibodyIBA 05/2001
1	Biomarkers (Surrogate Marker)IBA 01/2001
1	Ephrin-B2 (Ephrin B2)IBA 12/2000
1	Morphine (MS Contin)FDA LinkGeneric 11/2000
1	KetorolacIBA 11/2000
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2000
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2000
1	Etoposide (VP 16)FDA LinkGeneric 11/2000
1	Cisplatin (Platino)FDA LinkGeneric 11/2000
1	trioctyl phosphine oxide (TOPO)IBA 11/2000
1	Erythropoietin FDA Link 09/2000
1	Phosphotransferases (Kinase)IBA 09/2000
1	EphrinsIBA 09/2000
1	tyrosine receptor (receptor, tyrosine)IBA 09/2000
1	ELAV-Like Protein 4IBA 07/2000
1	GangliosidesIBA 07/2000
1	Complement Inactivating AgentsIBA 06/2000
1	RNA (Ribonucleic Acid)IBA 03/2000
1	Topoisomerase II InhibitorsIBA 03/2000
1	Membrane Cofactor ProteinIBA 03/2000

Therapy/Procedure

15	Therapeutics 01/2017 - 03/2000
7	Drug Therapy (Chemotherapy) 07/2001 - 03/2000
5	Immunotherapy 07/2015 - 03/2000
3	Radiotherapy 09/2001 - 01/2001
2	Radioimmunotherapy 01/2001 - 12/2000
2	Combination Drug Therapy (Combination Chemotherapy) 11/2000 - 11/2000
1	Aftercare (After-Treatment) 01/2017
1	Length of Stay 01/2017
1	Bioreactors (Bioreactor) 01/2017
1	Patient Readmission 01/2017
1	Resuscitation 06/2007
1	CVACE protocol 01/2001
1	Lasers (Laser) 12/2000
1	Transplantation 11/2000